May 05, 2026 -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The Euro

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), based on the CAPItello-281 Phase III trial. The Committee voted 7 to 1, with 1 abstaining. In August 2025, the FDA accepted the supplemental New Drug

AI-Driven Field Insights Drive Pharmaceutical Brand Performance in World’s Largest Market April 30, 2026 -- KAI Conversations, an AI-powered conversation intelligence platform purpose-built for the pharmaceutical industry, today announced a strategic partnership with Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, to bring AI-driven field insights to the U.S. biopharma market. Pharmaceutical companies invest an estimated 30–50% of revenue in field teams,

Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards ELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links bet

April 30, 2026 — La Jolla Labs,Inc. today announced that the first patient has been treated with GBFsen, a custom-designed antisense oligonucleotide (ASO) therapy developed to target a TDP-4 patient-specific mutation associated with an inherited, ultra-rare form of amyotrophic lateral sclerosis (ALS). The patient was diagnosed one year ago with a rapidly progressive form of ALS driven by a mutation in the prion-like domain of TDP-43. With no approved therapies, no clinical protocols, and no es

China-based Huahui Health has granted BeOne Medicines (Nasdaq: ONC) a global exclusive option over HH160, a preclinical trispecific antibody targeting PD-1, CTLA-4, and VEGF-A simultaneously, in a cancer immunotherapy collaboration that carries a headline value of up to USD 2.02 billion. Under the agreement, BeOne Medicines (NASDAQ: ONC) pays an upfront USD 20 million to secure the option, with a further USD 100 million due upon formal exercise. Huahui Health, a privately held Beijing-based biop

April 29, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a novel, selective, oral inhibi

Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates New patent will provide IP protection of Breast Cancer Vaccine in Mexico into 2040 April 29, 2026 -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent Num

April 29, 2026 -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application experience of its investigational drug candidate ENERGI-F703DFU at the European Wound Management Association (EWMA) 2026 Annual Conference, to be held May 5-7, 2026, in Bremen, Germany. The presentation, titled "ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foo

Dual Designations Affirm Significant Unmet Need; Multi-Year Phase 1 Data Published in the New England Journal of Medicine Underpin Advancement to Phase 2 April 29, 2026 -- Expression Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a curative autologous stem cell therapy for hemophilia A, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation and Rare Pediatric Disease Designation to its investigational therapy. The dual desi